Effects of Switching from Fenofibrate to Pemafibrate for Asymptomatic Primary Biliary Cholangitis

The PPARs:  From Orphan Receptors to Drug Discovery

Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · see citing works

Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease

Smit, J., Schinkel, A. H., Elferink, R. P. J. O., Groen, A. K., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., Ottenhoff, R., van der Lugt, N. M. T., van ROON, M. A., et al. (1993) · Cell · doi:10.1016/0092-8674(93)90380-9 · Cited by 1,443 · see citing works

Primary Biliary Cirrhosis

Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241 · see citing works

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216 · see citing works

Primary biliary cirrhosis # †

Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099 · see citing works

Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid

Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · see citing works

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

Poupon, R., Lindor, K., Cauch-Dudek, K., Dickson, E., Poupon, R., & Heathcote, E. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70183-5 · Cited by 648 · see citing works

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis

Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 635 · see citing works

Bile Acids Induce the Expression of the Human Peroxisome Proliferator-Activated Receptor α Gene via Activation of the Farnesoid X Receptor

Pineda‐Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J., & Staels, B. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0120 · Cited by 485 · see citing works

Primary biliary cirrhosis

Talwalkar, J. A., & Lindor, K. D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13808-1 · Cited by 299 · see citing works

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

Honda, A., Ikegami, T., Nakamuta, M., Miyazaki, T., Iwamoto, J., Hirayama, T., Saito, Y., Takikawa, H., Imawari, M., & Matsuzaki, Y. (2013) · Hepatology · doi:10.1002/hep.26018 · Cited by 210 · see citing works

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Ishibashi, S., Yamashita, S., Arai, H., Araki, E., Yokote, K., Suganami, H., Fruchart, J.-C., & Kodama, T. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.029 · Cited by 208 · see citing works

Effects of Fibrates in Kidney Disease

Jun, M., Zhu, B., Tonelli, M., Jardine, M. J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., & Perkovic, V. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.049 · Cited by 189 · see citing works

Fenofibrate Increases Creatininemia by Increasing Metabolic Production of Creatinine

Hottelart, C., El Esper, N., Rose, F., Achard, J.-M., & Fournier, A. (2002) · Nephron · doi:10.1159/000064083 · Cited by 186 · see citing works

Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid: Pilot study: fenofibrate with UDCA for primary biliary cirrhosis

Levy, C., Peter, J. A., Nelson, D. R., Keach, J., Petz, J., Cabrera, R., Clark, V., Firpi, R. J., Morelli, G., Soldevila-Pico, C., et al. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04512.x · Cited by 186 · see citing works

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Ishibashi, S., Arai, H., Yokote, K., Araki, E., Suganami, H., & Yamashita, S. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.10.006 · Cited by 184 · see citing works

Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients

Corpechot, C., Carrat, F., Poupon, R., & Poupon, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.31880 · Cited by 169 · see citing works

Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis

Lindor, K. D., Jorgensen, R. A., Therneau, T. M., Malinchoc, M., & Dickson, E. R. (1997) · Mayo Clinic Proceedings · doi:10.4065/72.12.1137 · Cited by 166 · see citing works

The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study

Iwasaki, S., Ohira, H., Nishiguchi, S., Zeniya, M., Kaneko, S., Onji, M., Ishibashi, H., Sakaida, I., Kuriyama, S., Ichida, T., et al. (2008) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00305.x · Cited by 145 · see citing works

Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse

José Chianale, B., Vollrath, V., Wielandt, A. M., Amigo, L., Rigotti, A., Nervi, F. O., González, S., ANDRADE, L., Pizarro, M., & Luigi Accatino, L. (1996) · Biochemical Journal · doi:10.1042/bj3140781 · Cited by 143 · see citing works

Combined ursodeoxycholic acid (<scp>UDCA</scp>) and fenofibrate in primary biliary cholangitis patients with incomplete<scp>UDCA</scp>response may improve outcomes

Cheung, A. C., Lapointe‐Shaw, L., Kowgier, M., Meza‐Cardona, J., Hirschfield, G. M., Janssen, H. L. A., & Feld, J. J. (2016) · Alimentary Pharmacology &amp; Therapeutics · doi:10.1111/apt.13465 · Cited by 139 · see citing works

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

Arai, H., Yamashita, S., Yokote, K., Araki, E., Suganami, H., Ishibashi, S., & on behalf of the K-877 Study Group (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.44412 · Cited by 136 · see citing works

Bezafibrate treatment: a new medical approach for PBC patients?

Kanda, T., Yokosuka, O., Imazeki, F., & Saisho, H. (2003) · Journal of Gastroenterology · doi:10.1007/s00535-002-1102-7 · Cited by 129 · see citing works

Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: Results of a 14-year cohort study

Zhang, L.-N., Shi, T.-Y., Shi, X.-H., Wang, L., Yang, Y.-J., Liu, B., Gao, L.-X., Shuai, Z.-W., Kong, F., Chen, H., et al. (2013) · Hepatology · doi:10.1002/hep.26322 · Cited by 113 · see citing works

Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study

Nakai, S., Masaki, T., Kurokohchi, K., Deguchi, A., & Nishioka, M. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01667.x · Cited by 113 · see citing works

Deterioration in renal function associated with fibrate therapy.

Lipscombe, J., Lewis, G. F., Cattran, D. C., & Bargman, J. M. (2001) · PubMed · Cited by 111 · see citing works

Guidelines for the management of primary biliary cirrhosis

Cirrhosis, W. S. (. V. F. C. P. G. F. P. B. (2014) · Hepatology Research · doi:10.1111/hepr.12270 · Cited by 111 · see citing works

Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid

Lens, S., Leoz, M., Nazal, L., Bruguera, M., & Parés, A. (2014) · Liver International · doi:10.1111/liv.12290 · Cited by 107 · see citing works

Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver

Gebel, T., Arand, M., & Oesch, F. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80734-x · Cited by 106 · see citing works

Fenofibrate for patients with asymptomatic primary biliary cirrhosis

Dohmen, K., Mizuta, T., Nakamuta, M., Shimohashi, N., Ishibashi, H., & Yamamoto, K. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i6.894 · Cited by 99 · see citing works

Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score

Hegade, V. S., Khanna, A., Walker, L. J., Wong, L.-L., Dyson, J. K., & Jones, D. E. J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4250-y · Cited by 86 · see citing works

Fenofibrate treatment in patients with primary biliary cirrhosis

Ohira, H., Sato, Y., Ueno, T., & Sata, M. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05944.x · Cited by 82 · see citing works

Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes

Forsblom, C., Hiukka, A., Leinonen, E. S., Sundvall, J., Groop, P.-H., & Taskinen, M.-R. (2010) · Diabetes Care · doi:10.2337/dc09-0621 · Cited by 81 · see citing works

Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis

Jun, I. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.04.001 · Cited by 80 · see citing works

Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study

Liberopoulos, E. N., Florentin, M., Elisaf, M., Mikhailidis, D. P., & Tsianos, E. V. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010120 · Cited by 74 · see citing works

Effect of Fenofibrate on Uric Acid Metabolism and Urate Transporter 1

Uetake, D., Ohno, I., Ichida, K., Yamaguchi, Y., Saikawa, H., Endou, H., & Hosoya, T. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.2597 · Cited by 73 · see citing works

A 35‐year follow‐up of a large cohort of patients with primary biliary cirrhosis seen at a single centre

Floreani, A., Caroli, D., Variola, A., Rizzotto, E. R., Antoniazzi, S., Chiaramonte, M., Cazzagon, N., Brombin, C., Salmaso, L., & Baldo, V. (2011) · Liver international (Print) · doi:10.1111/j.1478-3231.2010.02366.x · Cited by 72 · see citing works

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases

Yamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 68 · see citing works

Bezafibrate Treatment of Primary Biliary Cirrhosis Following Incomplete Response to Ursodeoxycholic Acid

Hazzan, R., & Tur‐Kaspa, R. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181c115b3 · Cited by 63 · see citing works

Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy

Xiao, H., Wang, Q., Liu, Y., Zheng Rui, Y. O. U., Zhao Lian, B. I. A. N., Qiu, D., & Ma, X. (2012) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2012.00574.x · Cited by 63 · see citing works

Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol

Ghonem, N. S., Auclair, A. M., Hemme, C. L., Gallucci, G. M., de la Rosa Rodriguez, R., Boyer, J. L., & Assis, D. N. (2020) · Clinical Pharmacology &amp; Therapeutics · doi:10.1002/cpt.1930 · Cited by 57 · see citing works

Comment on biochemical response to ursodeoxycholic acid and long‐term prognosis in primary biliary cirrhosis†

Walker, L. J., Newton, J. L., Jones, D. E. J., & Bassendine, M. F. (2008) · Hepatology · doi:10.1002/hep.22670 · Cited by 43 · see citing works

Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis

Joshita, S., Umemura, T., Yamashita, Y., Sugiura, A., Yamazaki, T., Fujimori, N., Matsumoto, A., & Tanaka, E. (2019) · Hepatology Research · doi:10.1111/hepr.13361 · Cited by 38 · see citing works

Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come

Ghonem, N. S., & Boyer, J. L. (2012) · Hepatology · doi:10.1002/hep.26155 · Cited by 38 · see citing works

Fibrate treatment for primary biliary cirrhosis

Cuperus, F. J. C., Halilbasic, E., & Trauner, M. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000056 · Cited by 36 · see citing works

Effect of Fenofibrate Medication on Renal Function

Kim, S., Ko, K., Park, S., Lee, D. R., & Lee, J. (2017) · Korean Journal of Family Medicine · doi:10.4082/kjfm.2017.38.4.192 · Cited by 34 · see citing works

Fibrate therapy and renal function

Sica, D. A. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0051-5 · Cited by 33 · see citing works

Fenofibrate-Induced Acute Renal Failure Due to Massive Rhabdomyolysis after Coadministration of Statin in Two Patients

Ünal, A., Torun, E., Sipahioğlu, M. H., Tokgöz, B., Kaya, M. G., Oymak, O., & Utaş, C. (2008) · Internal Medicine · doi:10.2169/internalmedicine.47.0939 · Cited by 30 · see citing works

Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA

Duan, W., Ou, X., Wang, X., Wang, Y., Zhao, X., Wang, Q., Wu, X., Zhang, W., Ma, H., You, H., et al. (2018) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2018.5533/2018 · Cited by 30 · see citing works

Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate

Matsumoto, T. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.08.015 · Cited by 28 · see citing works

Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.

Dohmen, K., Tanaka, H., & Haruno, M. (2013) · PubMed · doi:10.15017/1398604 · Cited by 24 · see citing works

Changing nomenclature for PBC from “primary biliary cirrhosis” to “primary biliary cholangitis”

Tanaka, A., Takikawa, H., Miwa, H., Shimosegawa, T., Mochida, S., & Koike, K. (2016) · Hepatology Research · doi:10.1111/hepr.12729 · Cited by 16 · see citing works

Biochemical and Histological Effectiveness of Long-term Use of Fenofibrate for Asymptomatic Primary Biliary Cholangitis

Dohmen, K., Tanaka, H., Haruno, M., & Aishima, S. (2016) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2016.05.635 · Cited by 3 · see citing works

Primary biliary cholangitis.

Tanaka, A., Ma, X., Takahashi, A., & Vierling, J. M. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01303-5 · Cited by 177 · see citing works

New Therapies on the Horizon for Primary Biliary Cholangitis

Tanaka, A. (2023) · Drugs · doi:10.1007/s40265-023-01979-1 · Cited by 31 · see citing works

Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?

Yang, Y., He, X.-S., Rojas, M., Leung, P. S. C., & Gao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1184252 · Cited by 29 · see citing works

Retinal degeneration induced in a mouse model of ischemia–reperfusion injury and its management by pemafibrate treatment

Lee, D., Nakai, A., Miwa, Y., Tomita, Y., Kunimi, H., Chen, J., Ikeda, S., Tsubota, K., Negishi, K., & Kurihara, T. (2022) · The FASEB Journal · doi:10.1096/fj.202200455rrr · Cited by 27 · see citing works

Effects of pemafibrate on primary biliary cholangitis with dyslipidemia

Yamaguchi, M., Asano, T., Arisaka, T., Mashima, H., Irisawa, A., & Tamano, M. (2022) · Hepatology Research · doi:10.1111/hepr.13747 · Cited by 23 · see citing works

Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis

Wang, C., Shi, Y., Wang, X., Ma, H., Liu, Q., Gao, Y., & Niu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940688 · Cited by 19 · see citing works

The Effect of Lipopolysaccharide-Stimulated Adipose-Derived Mesenchymal Stem Cells on NAFLD Treatment in High-Fat Diet-Fed Rats

Afarin, R., Aslani, F., Asadizade, S., Asl, B. J., Gahrooie, M. M., Shakerian, E., & Ahangarpour, A. (2023) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr-134807 · Cited by 17 · see citing works

Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease

Tamai, H., & Okamura, J. (2022) · Hepatology Research · doi:10.1111/hepr.13859 · Cited by 10 · see citing works

Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group

Tsuji, K., Tamaki, N., Kurosaki, M., Mori, N., Takaki, S., Ohya, K., Mashiba, T., Ochi, H., Kobashi, H., Ogawa, C., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14172 · Cited by 8 · see citing works

Primary biliary cholangitis: current insights and novel therapies

Granito, A., Παππάς, Γ., Napoli, L., Stefanini, B., Tirotta, D., & Muratori, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2672493 · Cited by 8 · see citing works

Revisiting PPAR agonists: novel perspectives in the treatment of primary biliary cholangitis

Chen, Y., Zheng, K., Da, G., Wang, X., Wei, Y., Wang, G., Zhang, F., & Wang, L. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2406268 · Cited by 5 · see citing works

Drug-induced rise in serum creatinine: cystatin C to the rescue? Evidence, pitfalls and knowledge gaps

Regemorter, E. V., Ponlot, E., Boland, L., Gillion, V., & Devresse, A. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106592 · Cited by 2 · see citing works

Biochemical and Plasma Lipid Responses to Pemafibrate in Patients With Primary Biliary Cholangitis and Dyslipidemia: A Four-Year Analysis

Kobayashi, H., Sugiura, A., Koyama-Otagiri, M., Nimura, T., Kurasawa, Y., Shirakawa, H., & Joshita, S. (2025) · Cureus · doi:10.7759/cureus.83176 · Cited by 1 · see citing works

Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis

Tanigawa, R., Ueno, Y., Takahashi, H., Saito, A., Suganami, H., & Tanaka, A. (2026) · Hepatology Research · doi:10.1111/hepr.70244 · Cited by 1 · see citing works

Long-term effects of switching from fenofibrate to pemafibrate for asymptomatic primary biliary cholangitis (aPBC)

Dohmen, K., Onohara, S.-Y., & Harada, S. (2023) · Kanzo · doi:10.2957/kanzo.64.318

Renal Handling of Lithium

Meyer, J. M., & Stahl, S. M. (2023) · Cambridge University Press eBooks · doi:10.1017/9781009225069.005

New therapies for primary biliary cholangitis usher in a personalised approach to treatment

France, N. L. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01129-x

New therapies for primary biliary cholangitis

Sohal, A., Alamgir, M., & Kowdley, K. V. (2026) · Hepatology International · doi:10.1007/s12072-026-11088-2

Long-term effects of switching from fenofibrate to pemafibrate for asymptomatic primary biliary cholangitis (aPBC)

Dohmen, K., Onohara, S.-Y., & Harada, S. (2023) · Kanzo · doi:10.2957/kanzo.64.318

Effects of pemafibrate on primary biliary cholangitis with dyslipidemia

Yamaguchi, M., Asano, T., Arisaka, T., Mashima, H., Irisawa, A., & Tamano, M. (2022) · Hepatology Research · doi:10.1111/hepr.13747 · Cited by 23 · see citing works

Long-term effect of biochemical response to ursodeoxycholic acid and pemafibrate switching from bezafibrate in patients with primary biliary cholangitis due to renal dysfunction

Nakayama, H., Satou, K., Anzai, K., Watanabe, O., Takai, S., & Sugai, Y. (2022) · Kanzo · doi:10.2957/kanzo.63.392 · Cited by 1 · see citing works

Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis

Joshita, S., Umemura, T., Yamashita, Y., Sugiura, A., Yamazaki, T., Fujimori, N., Matsumoto, A., & Tanaka, E. (2019) · Hepatology Research · doi:10.1111/hepr.13361 · Cited by 38 · see citing works

Biochemical and Plasma Lipid Responses to Pemafibrate in Patients With Primary Biliary Cholangitis and Dyslipidemia: A Four-Year Analysis

Kobayashi, H., Sugiura, A., Koyama-Otagiri, M., Nimura, T., Kurasawa, Y., Shirakawa, H., & Joshita, S. (2025) · Cureus · doi:10.7759/cureus.83176 · Cited by 1 · see citing works